61 related articles for article (PubMed ID: 7979183)
1. Conformational changes in membrane proteins of multidrug-resistant K562 and primary rat hepatocyte cultures as studied by Fourier transform infrared spectroscopy.
Le Gal JM; Morjani H; Fardel O; Guillouzo A; Manfait M
Anticancer Res; 1994; 14(4A):1541-8. PubMed ID: 7979183
[TBL] [Abstract][Full Text] [Related]
2. Ultrastructural appraisal of the multidrug resistance in K562 and LR73 cell lines from Fourier transform infrared spectroscopy.
Le Gal JM; Morjani H; Manfait M
Cancer Res; 1993 Aug; 53(16):3681-6. PubMed ID: 8339276
[TBL] [Abstract][Full Text] [Related]
3. Combined Fourier transform infrared and Raman spectroscopic approach for identification of multidrug resistance phenotype in cancer cell lines.
Krishna CM; Kegelaer G; Adt I; Rubin S; Kartha VB; Manfait M; Sockalingum GD
Biopolymers; 2006 Aug; 82(5):462-70. PubMed ID: 16493658
[TBL] [Abstract][Full Text] [Related]
4. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
[TBL] [Abstract][Full Text] [Related]
5. Proton nuclear magnetic resonance spectroscopy reveals cellular lipids involved in resistance to adriamycin and taxol by the K562 leukemia cell line.
Le Moyec L; Tatoud R; Degeorges A; Calabresse C; Bauza G; Eugène M; Calvo F
Cancer Res; 1996 Aug; 56(15):3461-7. PubMed ID: 8758912
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells.
Munteanu E; Verdier M; Grandjean-Forestier F; Stenger C; Jayat-Vignoles C; Huet S; Robert J; Ratinaud MH
Biochem Pharmacol; 2006 Apr; 71(8):1162-74. PubMed ID: 16499877
[TBL] [Abstract][Full Text] [Related]
7. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
Arora A; Seth K; Kalra N; Shukla Y
Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829
[TBL] [Abstract][Full Text] [Related]
8. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
[TBL] [Abstract][Full Text] [Related]
9. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1.
Ye X; Liu T; Gong Y; Zheng B; Meng W; Leng Y
Leuk Res; 2009 Aug; 33(8):1114-9. PubMed ID: 19036441
[TBL] [Abstract][Full Text] [Related]
10. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
11. Development of doxorubicin resistant rat prostate cancer cell lines.
Replogle-Schwab TS; Schwab ED; Pienta KJ
Anticancer Res; 1997; 17(6D):4535-8. PubMed ID: 9494564
[TBL] [Abstract][Full Text] [Related]
12. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines.
Johnstone SA; Gelmon K; Mayer LD; Hancock RE; Bally MB
Anticancer Drug Des; 2000 Apr; 15(2):151-60. PubMed ID: 10901303
[TBL] [Abstract][Full Text] [Related]
13. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM
Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675
[TBL] [Abstract][Full Text] [Related]
14. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
Mankhetkorn S; Dubru F; Hesschenbrouck J; Fiallo M; Garnier-Suillerot A
Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093
[TBL] [Abstract][Full Text] [Related]
15. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
[TBL] [Abstract][Full Text] [Related]
16. Immunotoxin resistance in multidrug resistant cells.
McGrath MS; Rosenblum MG; Philips MR; Scheinberg DA
Cancer Res; 2003 Jan; 63(1):72-9. PubMed ID: 12517780
[TBL] [Abstract][Full Text] [Related]
17. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells.
Gayet L; Dayan G; Barakat S; Labialle S; Michaud M; Cogne S; Mazane A; Coleman AW; Rigal D; Baggetto LG
Biochemistry; 2005 Mar; 44(11):4499-509. PubMed ID: 15766280
[TBL] [Abstract][Full Text] [Related]
18. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
19. Reversal of P-glycoprotein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver.
Arora A; Seth K; Shukla Y
Carcinogenesis; 2004 Jun; 25(6):941-9. PubMed ID: 14729595
[TBL] [Abstract][Full Text] [Related]
20. MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol.
Li L; Jiang AC; Dong P; Wang H; Xu W; Xu C
Ann Surg Oncol; 2009 May; 16(5):1421-8. PubMed ID: 19247716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]